Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07645924 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine
A Phase 3 study, sponsored by Kallyope.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 1,800
- Enrollment target
NCT07645924: Recruiting Phase 3 study, sponsored by Kallyope.
NCT07645924 is a Phase 3 study that is actively recruiting participants, run by Kallyope. The registered enrollment target is 1,800 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07645924, a Phase 3 study, is actively recruiting participants, sponsored by Kallyope.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,800 participants
- Enrollment target
Study Summary
This is a double-blind, randomized, multicenter, outpatient evaluation of the efficacy, safety, and tolerability of elismetrep, as compared with placebo, in the acute treatment of migraine.
Interventions
- DRUG Placebo
- DRUG Elismetrep
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,800 participants |
| Start Date | 2026-07 |
| Est. Completion | 2027-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07645924
The ClinicalTrials.gov registry entry for NCT07645924 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 1,800 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kallyope, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07645924 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07645924 about?
NCT07645924 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine". This is a double-blind, randomized, multicenter, outpatient evaluation of the efficacy, safety, and tolerability of elismetrep, as compared with placebo, in the acute treatment of migraine.
What is the current status of trial NCT07645924?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,800 participants. The study started on 2026-07. Estimated completion is 2027-02.
What interventions are being tested in trial NCT07645924?
The interventions under investigation include: Placebo (DRUG), Elismetrep (DRUG).
Who is sponsoring clinical trial NCT07645924?
This trial is sponsored by Kallyope, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.